Abstract
Tamibarotene (Am80) is a synthetic retinoid and has been approved for treatment of relapsed or refractory acute promyelocytic leukemia (APL) in Japan. It is a potentially safer oral retinoid drug that exhibits a high selectivity for retinoic acid receptor (RAR) α/β-subtypes and a good pharmacokinetic profile. Various preclinical studies suggest that tamibarotene has a pleiotropic effect as a potential therapeutic for Alzheimer’s disease (AD). At present, a pilot investigator-sponsored clinical trial in Japan is ongoing to prove the efficacy and safety of tamibarotene for moderate AD patients.
